Xeljanz Development Plans Scaled Back By Pfizer
This article was originally published in Scrip
Executive Summary
You may also be interested in...
Ex-Pfizer Employee Overseeing Xeljanz Global Marketing Sued For Trade Secret Theft
Pfizer says its former global marketing director emailed and copied hundreds of documents on product launch plans and steps to obtain government approvals before leaving the company in January.
Pfizer Assembling New Commercial Team For Move Into Dermatology
The big pharma is moving into a new therapy area – dermatology – as part of a three-pronged strategy in Inflammation & Immunology that also includes rheumatology and gastroenterology. Pfizer’s first product for dermatology, crisaborole for atopic dermatitis, could launch next year.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.